Scisparc Stock Price, News & Analysis
Company Description
SciSparc Ltd. (Nasdaq: SPRC) is a specialty, clinical-stage pharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, SciSparc focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals, primarily through clinical-stage drug development programs and related intellectual property.
The company conducts its core pharmaceutical activities through its majority-owned subsidiary NeuroThera Labs Inc. (TSXV: NTLX), a publicly traded company on the TSX Venture Exchange in Canada. SciSparc holds a controlling interest in NeuroThera and has transferred its advanced clinical-stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc. to NeuroThera under an asset and share purchase agreement. Following this transaction, NeuroThera changed its name from Miza III Ventures Inc. to NeuroThera Labs Inc. and is expected to be active in both pharmaceutical and supplemental sectors.
Core Pharmaceutical Focus
According to multiple company press releases, SciSparc’s pharmaceutical activities are centered on cannabinoid-based drug candidates that use THC and/or non-psychoactive CBD. The company, together with NeuroThera, reports engagement in the following drug development programs:
- SCI-110 – a program based on THC and/or non-psychoactive CBD for the treatment of Tourette syndrome, and for the treatment of Alzheimer’s disease and agitation.
- SCI-210 – a program based on THC and/or non-psychoactive CBD for the treatment of autism spectrum disorder (ASD) and status epilepticus.
These programs are described by the company as clinical-stage developments targeting central nervous system (CNS) and neurological conditions, including rare or difficult-to-treat disorders.
Subsidiaries and Nutraceutical Activities
In addition to its clinical-stage pharmaceutical work, SciSparc, through NeuroThera Labs Inc., holds a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. This activity aligns with the company’s broader focus on cannabinoid-related products and supplements, and is distinct from its regulated drug development programs.
Earlier disclosures also describe SciSparc as operating two reportable segments: (1) development of drugs based on cannabinoid molecules to be approved by an official regulatory authority, and (2) online sales of a range of hemp-based products. These hemp-based products include hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, anti-aging creams, and other beauty and hair treatment products manufactured in the United States.
Intellectual Property and Patent Portfolio
SciSparc emphasizes intellectual property as a key asset. The company and NeuroThera have reported several IP-related developments:
- Opioid–N-acylethanolamine platform: NeuroThera has been granted a patent by the Israel Patent Office for a proprietary combination of opioids and N-acylethanolamines (such as palmitoylethanolamide, PEA). This patent covers methods and formulations designed to potentiate opioid therapeutic effects while reducing side effects like tolerance, dependence, and gastrointestinal issues. The company notes that related patents have previously been granted in Europe, Japan, Australia, and Canada.
- MEAI and N-acylethanolamines for depression: NeuroThera, in collaboration with Clearmind Medicine Inc., has filed an Israeli patent application for a combination therapy using 5-methoxy-2-aminoindane (MEAI) and N-acylethanolamines, such as PEA, targeting depression. The collaboration has led to multiple patent filings for MEAI and N-acylethanolamines combinations for conditions including alcohol use disorder, cocaine addiction, obesity and weight loss, and depression.
These IP developments are positioned by the company as part of a broader strategy to build proprietary platforms in CNS-related therapeutics, including pain management and neuropsychiatric indications.
Endoscopy and GERD Device IP Acquisition
SciSparc has also entered into the medical device and endoscopy space through an agreement to acquire a treasury of patents, trademarks, know-how, and related intellectual property rights from Xylo Technologies Ltd. The portfolio is mainly associated with the MUSE™ system, described as a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (GERD).
Under a binding term sheet and subsequent definitive agreement, SciSparc agreed to acquire this IP portfolio in consideration for ordinary shares representing 19.99% of its issued and outstanding share capital at closing, or pre-funded warrants in lieu of some or all of those shares, subject to customary closing conditions and any required approvals. The company highlights Xylo’s prior commercialization of the MUSE system in Greater China through a licensing and distribution agreement with a Shanghai-based medical instruments company, under which Xylo received an upfront payment.
SciSparc has publicly stated that it intends to commence commercialization of these patented technologies following closing and to pursue exclusive partnerships with regional distributors in territories such as North America, Europe, and Latin America, aiming to replicate Xylo’s licensing model.
Quantum Computing and AI Drug Discovery Initiative
The company has announced an initiative to apply quantum computing-enabled 3D protein modeling to drug discovery. According to SciSparc’s disclosures, this program aims to develop quantum-enabled tools to:
- Predict how proteins fold into their three-dimensional shapes.
- Model protein–ligand interactions.
- Accelerate discovery of new drugs by improving the precision of structural predictions.
SciSparc has indicated that it plans to form a dedicated research team, collaborate with experts in quantum computing and structural biology, and incorporate a wholly owned Israeli subsidiary to operate this initiative. The initial focus is described as targeting applications in drug discovery for neurological and rare diseases, which aligns with the company’s existing CNS and cannabinoid-based programs.
In a related direction, NeuroThera has signed a non-binding term sheet to acquire a majority stake in an Israeli quantum computing bio data company focused on quantum-enabled clinical analytics. This potential acquisition, if completed, would give NeuroThera a 55% equity interest in the target company in exchange for NeuroThera shares, subject to due diligence, definitive agreements, and regulatory approvals.
Corporate Transactions and Portfolio Repositioning
SciSparc has engaged in several notable corporate transactions:
- Transfer of clinical-stage portfolio to NeuroThera: Under an asset and share purchase agreement, SciSparc transferred its advanced clinical-stage pharmaceutical portfolio and its majority stake in SciSparc Nutraceuticals Inc. to NeuroThera, receiving common shares, warrants, and contingent rights in NeuroThera. As a result, SciSparc holds a controlling interest in NeuroThera.
- Sale of MitoCareX Bio Ltd.: SciSparc sold its majority-owned subsidiary MitoCareX Bio Ltd. to N2OFF, Inc. MitoCareX focuses on drug discovery for resistant cancers, using a proprietary algorithm (MITOLINE™) for 3D comparative modeling of mitochondrial SLC25 proteins and in-vitro screening systems related to mitochondria. Following the transaction, MitoCareX became a wholly owned subsidiary of N2OFF.
- Framework agreement with AutoMax Motors Ltd.: SciSparc entered into a framework agreement that terminated a prior merger agreement with AutoMax Motors Ltd. and set out repayment terms for loans previously extended by SciSparc to AutoMax.
These transactions illustrate SciSparc’s focus on CNS, cannabinoid-based therapeutics, and related technologies, while monetizing or repositioning other assets such as oncology-focused subsidiaries.
Listing and Regulatory Status
SciSparc’s ordinary shares trade on the Nasdaq Capital Market under the symbol SPRC. The company has reported receiving a Nasdaq notification regarding non-compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), based on stockholders’ equity reported as of June 30, 2025. SciSparc has a period to submit a plan to regain compliance, and the notification letter does not have an immediate effect on the listing of its ordinary shares during the applicable grace period.
As a foreign private issuer, SciSparc files reports on Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission. Recent 6-K filings have covered financial statements, management’s discussion and analysis, patent-related announcements, corporate transactions, and capital markets activities such as warrant inducement agreements.
Business Model and Revenue Sources
Based on available disclosures, SciSparc’s business model combines:
- Clinical-stage drug development in CNS and neurological indications using cannabinoid-based compounds (THC and non-psychoactive CBD), mainly through its controlling interest in NeuroThera Labs Inc.
- Ownership and development of intellectual property in areas such as opioid–N-acylethanolamine combinations, MEAI-based neuroplastogen therapies, and GERD-related endoscopic devices (MUSE system and related IP).
- Nutraceutical and hemp seed oil-based product sales through a subsidiary that operates on the Amazon.com Marketplace.
The company’s activities span regulated pharmaceutical R&D, IP-driven medical technologies, and consumer-facing hemp seed oil-based products, all anchored in cannabinoid and related therapeutic platforms.